Anti-Human CD2 Reference Antibody (BTI-322, RUO) (HY113026)

Name: Anti-Human CD2 Reference Antibody (BTI-322, RUO)
Brand: abinScience
SKU: HY113026
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY113026
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	BTI-322
Biological activity	BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease [1] [2].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Erythrocyte receptor, SRBC, T-cell surface antigen CD2, Rosette receptor, CD2, LFA-3 receptor, T-cell surface antigen T11/Leu-5, LFA-2
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P06729
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	BTI-322, BTI322, BTI322
Background	T-cell surface antigen CD2 (LFA-2/OX-34) is a ~39 kDa protein. CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function.
References	1. Przepiorka, D., et al., (1998). A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood, 92(11), 4066–4071. [HY113026] 2. Xu, Y., et al., (2004). The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. Clinical and experimental immunology, 138(3), 476–483. [HY113026]
Note	For research use only. Not suitable for clinical or therapeutic use.